Form 4: Pacira CMO Plans Stock Sale Under 10b5-1 Plan
Insider Transaction Report
Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, filed a Form 4 indicating a future sale of 3,261 shares of common stock on March 17, 2026, under a pre-arranged 10b5-1 trading plan.
Summary
- Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, Inc. (PCRX), reported a planned sale of common stock.
- The transaction involves the disposition of 3,261 shares of common stock.
- The sale is scheduled to occur on March 17, 2026, at a price of $22.82 per share.
- Following this transaction, Mr. Slonin will beneficially own 223,640.175 shares of common stock.
- The sale is being executed pursuant to a Rule 10b5-1 trading plan, which was adopted on August 12, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, pre-planned transaction under a 10b5-1 plan, which typically does not signal a change in management's outlook on the company's prospects.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the planned insider stock transaction.
Industry Context
StockSavvy.ai notes that insider sales executed under a Rule 10b5-1 trading plan are pre-scheduled and generally do not reflect new discretionary decisions by the insider based on material non-public information. Such plans are common for executives to manage personal finances while complying with insider trading regulations.
Stakeholder Impact
- Shareholders: Minimal impact, as the sale is pre-planned and not indicative of new material information. It represents a small portion of the insider's total holdings.
Key Dates
| Date | Description |
|---|---|
| 08/12/2025 | Date Rule 10b5-1 trading plan was adopted by Jonathan Slonin. |
| 03/17/2026 | Date of planned common stock transaction (sale). |
| 03/19/2026 | Date the Form 4 was signed by the attorney-in-fact for Jonathan Slonin. |
Recommendation
holdThe sale by the Chief Medical Officer is a pre-scheduled event under a 10b5-1 trading plan, adopted well in advance. This type of transaction is generally considered routine and does not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate.
Keywords
Pacira BioSciences, PCRX, Jonathan Slonin, Chief Medical Officer, Insider Trading, Form 4, 10b5-1 Plan, Stock Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.